相关实验视频

Updated: Jan 13, 2026

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

使用鱼血模型来优先考虑药品,并保护鱼免受潜在的不良影响

James P Meador¹, Molly Shuman-Goodier²

¹University of Washington, Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, 98195, United States.

Environmental toxicology and chemistry

|January 8, 2026

概括

鱼类等离子体模型 (FPM) 有助于优先考虑在水生生态系统中对环境风险评估的药品. 这种方法可以识别潜在的有害药物,重点关注那些最有可能影响鱼类健康的药物.

科学领域:

环境毒理学环境毒理学
水生生态毒理学水生生态毒理学
药品风险评估药品风险评估药品风险评估

背景情况:

关于药物对水生生物的影响的数据有限.
现有的风险评估方法,如QSAR和细胞检测有局限性.
需要新的方法来评估药品的环境风险.

研究的目的:

利用鱼类等离子体模型 (FPM) 根据对水生生物群的潜在风险来优先考虑药品.
使用FPM评估常见处方药的环境相关性.
通过评估人类以太基因相关基因 (hERG) 活动以优先级来补充现有方法.

主要方法:

将鱼类等离子体模型 (FPM) 应用于通常处方的药品.
利用了全球地表水度数据库以及Cmax值.
使用响应比率 (RR ≥ 1) 和低暴露度 (1%Cmax ≤ 0.1 ng/mL) 优先考虑的活性药物成分 (API).

主要成果:

确定了57个具有RR ≥ 1的API和50个具有1%Cmax ≤0.1 ng/mL的API.
大多数优先考虑的API (63) 属于六种药物类别:激素,抗抑郁药,抗组胺药,抗胆固醇药,皮质类固醇药和抗高血压药.
激素 (21) 和抗抑郁药 (13) 是最常被优先考虑的药物类别.

结论:

在环境风险评估中,FPM是优先考虑药品的有价值工具.
该模型具有优势,因为它基于预期的低剂量体内生物效应.
FPM方法可以扩展到除了药品之外,还可以扩展到其他有毒性数据的化学品.

关键词:

这种基因与以太基因 (hERG) 有关.鱼类等离子体模型激素激素激素激素激素药品制品制品制品制品制品制品制品制品确定优先级,确定优先级.

更多相关视频

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...